x

Zoek een klinische studie of trial

* (*) verplicht veld

349 Resultaat/Resultaten

Aanwerving proef = Aanwerving proef
; Lopend onderzoek = Lopend onderzoek
; Gefinancierd door een IRDiRC-lid = ; Member of a ERN =

Nationale klinische studie(s)

USA

Washington
ADDRESS: NOT PROVIDED - US

USA

Washington
ADDRESS: NOT PROVIDED - US

USA

Washington
ADDRESS: NOT PROVIDED - US

USA

Washington
ADDRESS: NOT PROVIDED - US

Lopend onderzoek
Long-Term Follow-up Protocol for Subjects Treated with JCAR015 - GB
Institution: Information not provided - US

USA

Washington
ADDRESS: NOT PROVIDED - US

USA

Washington
ADDRESS: NOT PROVIDED - US

USA

Washington
ADDRESS: NOT PROVIDED - US

Aanwerving proef
Lopend onderzoek
Dose Optimization Study of Idelalisib in Follicular Lymphoma-GB
Institution: Information not provided - US

USA

Washington
ADDRESS: NOT PROVIDED - US

Multinationale klinische studie(s)

DUITSLAND

Rheinland-Pfalz
INGELHEIM AM RHEIN

FRANKRIJK

AUVERGNE-RHONE-ALPES
PIERRE-BENITE

FRANKRIJK

NOUVELLE AQUITAINE
LIMOGES

AMYDARA: A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better
CHU de Limoges - Hôpital Dupuytren
Délégation Régionale de la Recherche Clinique et de l'Innovation

USA

California
FOSTER CITY

Dose Optimization Study of Idelalisib in Follicular Lymphoma
GILEAD SCIENCES, INC.
Gilead Sciences, Inc

USA

California
LOS ANGELES

Phase 1 Study of Lorlatinib (PF-06463922), an Oral Small Molecule Inhibitor of ALK/ROS1, for Patients With ALK-Driven Relapsed or Refractory Neuroblastoma
Children's Hospital Los Angeles
New Approaches to Neuroblastoma Therapy consortium - NANT Operations Center

USA

Maryland
BETHESDA

USA

Maryland
SILVER SPRING

Gefinancierd door een IRDiRC-lidPhase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)
FDA - U.S. Food and Drug Administration
Food and Drug Administration

USA

Washington
ADDRESS: NOT PROVIDED - US

USA

Washington
ADDRESS: NOT PROVIDED - US

USA

Washington
ADDRESS: NOT PROVIDED - US

Long-Term Follow-up Protocol for Subjects Treated with JCAR015
Institution: Information not provided - US

USA

Washington
ADDRESS: NOT PROVIDED - US

USA

Washington
ADDRESS: NOT PROVIDED - US

USA

Washington
ADDRESS: NOT PROVIDED - US

USA

Washington
ADDRESS: NOT PROVIDED - US

Dose Optimization Study of Idelalisib in Follicular Lymphoma
Institution: Information not provided - US

USA

Washington
ADDRESS: NOT PROVIDED - US

USA

Washington
ADDRESS: NOT PROVIDED - US

USA

Washington
ADDRESS: NOT PROVIDED - US